BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ECC4703 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ECC4703\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07726368-8301@assetmemo.bio
DTSTAMP:20261121T004529Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ECC4703: Phase 1 readout est. (NCT07726368)
DESCRIPTION:ECC4703\, phase 1\, MASH / NASH.\nStudy: Study of ECC4703 With 
 Sulfasalazine and Pitavastatin\nEstimated primary completion: December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ecc4703#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07726368
URL:https://assetmemo.bio/drug/ecc4703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334080-8301@assetmemo.bio
DTSTAMP:20261121T004529Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:ECC4703: Phase 1 readout est. (NCT07334080)
DESCRIPTION:ECC4703\, phase 1\, MASH / NASH.\nStudy: ECC4703 Food Effect an
 d Relative Bioavailability Study in Healthy Adult Participants\nEstimated 
 primary completion: April 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ecc4703#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07334080
URL:https://assetmemo.bio/drug/ecc4703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288138-8301@assetmemo.bio
DTSTAMP:20261121T004529Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:ECC4703: Phase 2 readout est. (NCT07288138)
DESCRIPTION:ECC4703\, phase 2\, MASH / NASH.\nStudy: A Study of a Thyroid H
 ormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitiv
 e Amine Oxidase (SSAO) Inhibitor\, Alone and in Combination\, in Adults Wi
 th Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)\nEstim
 ated primary completion: 15 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ecc4703#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07288138
URL:https://assetmemo.bio/drug/ecc4703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
